Methodological advances in necroptosis research: From challenges to solutions

IF 7.6 Q1 ONCOLOGY

Journal of the National Cancer Center Pub Date : 2022-12-01 DOI:10.1016/j.jncc.2022.08.007

Peixing Wan, Jiong Yan, Zhenggang Liu

{"title":"Methodological advances in necroptosis research: From challenges to solutions","authors":"Peixing Wan, Jiong Yan, Zhenggang Liu","doi":"10.1016/j.jncc.2022.08.007","DOIUrl":null,"url":null,"abstract":"<div>Necroptosis is currently attracting the attention of the scientific community for its broad implications in inflammatory diseases and cancer. However, detecting ongoing necroptosis in vivo under both experimental and clinical disease conditions remains challenging. The technical barrier lies in four aspects, namely tissue sampling, real-time in vivo monitoring, specific markers, and distinction between different types of cell death. In this review, we presented the latest methodological advances for in vivo necroptosis identification. The advances highlighted the multi-parameter flow cytometry, sA5-YFP tool, radiolabeled Annexin V/Duramycin, Gallium-68-labeled IRDye800CW contrast agent, and SMART platform in vivo. We also discussed the up-to-date research models in studying necroptosis, particularly the mice models for manipulating and monitoring necroptosis. Based on these recent advances, this review aims to provide some advice on current necroptosis techniques and approaches.</div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 291-297"},"PeriodicalIF":7.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757602/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266700542200062X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Necroptosis is currently attracting the attention of the scientific community for its broad implications in inflammatory diseases and cancer. However, detecting ongoing necroptosis in vivo under both experimental and clinical disease conditions remains challenging. The technical barrier lies in four aspects, namely tissue sampling, real-time in vivo monitoring, specific markers, and distinction between different types of cell death. In this review, we presented the latest methodological advances for in vivo necroptosis identification. The advances highlighted the multi-parameter flow cytometry, sA5-YFP tool, radiolabeled Annexin V/Duramycin, Gallium-68-labeled IRDye800CW contrast agent, and SMART platform in vivo. We also discussed the up-to-date research models in studying necroptosis, particularly the mice models for manipulating and monitoring necroptosis. Based on these recent advances, this review aims to provide some advice on current necroptosis techniques and approaches.

查看原文本刊更多论文

坏死下垂研究的方法学进展:从挑战到解决方案

坏死性上睑下垂因其在炎症性疾病和癌症中的广泛意义而引起科学界的关注。然而，在实验和临床疾病条件下检测正在进行的坏死性上睑下垂仍然具有挑战性。技术障碍在于四个方面，即组织取样、活体实时监测、特异性标记、不同类型细胞死亡的区分。在这篇综述中，我们介绍了体内坏死性下垂鉴定的最新方法学进展。这些进展突出了多参数流式细胞术、sA5-YFP工具、放射性标记的膜联蛋白V/Duramycin、镓68标记的IRDye800CW造影剂和SMART体内平台。我们还讨论了研究坏死性上睑下垂的最新研究模型，特别是用于操纵和监测坏死性上睑下垂的小鼠模型。基于这些最新进展，本文综述旨在对目前的坏死下垂技术和方法提供一些建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the National Cancer Center Oncology

CiteScore

14.20

自引率

0.00%

发文量

审稿时长

70 days